Therapeutic Modulation of MAPK and NF-kappaB Signaling Pathways

This direction is merged into another direction: NF-κB pathway inhibition. Its last version stays readable and citable here.

Version 1 of 117 papers23 conceptsfrozen 2026-10-04

Cells navigate their environment through a complex relay of molecular signals. When these signals—specifically the Mitogen-Activated Protein Kinase (MAPK) and Nuclear Factor-kappa B (NF-κB) pathways—become dysregulated, they drive the progression of chronic inflammation, tissue scarring, and cancer. Recent research across diverse medical fields suggests that many effective therapies, from natural alkaloids to probiotics, work by "unplugging" these specific signaling relays.

The Signaling Relay as a Control Point

Think of a cell as a factory where the "on" switches for growth and defense are controlled by phosphorylation—the addition of a phosphate group to a protein. In a healthy state, these switches are temporary. However, in diseases like cancer or chronic inflammation, the switches get stuck in the "on" position.

The MAPK pathway is a primary relay system consisting of three main branches: ERK, JNK, and p38.

  • ERK typically governs growth and survival.
  • JNK and p38 often respond to stress and regulate inflammation or programmed cell death (apoptosis).

Researchers like Xueping Zhou have shown that inactivating the MEK/ERK cascade is a primary mechanism for stopping aggressive tumors. In their study on Cordycepin, they demonstrated that by inhibiting ERK phosphorylation, the treatment flips the cellular switch from "proliferate" to "die," effectively inducing apoptosis in esophageal cancer cells.

Restoring the Barrier through TLR4 and NF-κB

While the MAPK pathway often acts as the internal growth engine, the TLR4/NF-κB axis acts as the cell's "alarm system" for external threats. When this system is overactive, it compromises physical barriers in the body, such as the gut lining or the blood-milk barrier in mammary glands.

Jing Gong and colleagues found that Berberine attenuates intestinal dysfunction in diabetic rats by suppressing the TLR4/MyD88/NF-κB signaling cascade. By quieting this alarm, the body can repair the "leaky gut," reducing systemic inflammation. Similarly, Yuanyuan Liu demonstrated that Houttuynia essential oil protects against mastitis by blocking the phosphorylation of ERK1/2 and p38, which restores the structural integrity of the blood-milk barrier.

Strategic Suppression in Cancer and Remodeling

In oncology, the goal is often to "unleash" stress signals or "choke" survival signals.

  • Unleashing Stress: Koichi Ito identified that the kinase PTK6 acts as a brake on the p38 MAPK pathway in breast cancer. By inhibiting PTK6, the p38 stress pathway is hyper-activated, forcing the resistant cancer cells into programmed death.
  • Choking Survival: Zhen Ding showed that the cholesterol inhibitor RO 48-8071 deactivates JNK and ERK pathways, cutting off the metabolic engine that pancreatic cancer cells need to survive.

This logic extends to chronic organ damage. In hypertensive heart disease, the heart tissue often thickens and scars—a process called remodeling. Fen Ai found that Schisandrin B prevents this damage by inhibiting the MAPK pathway, specifically suppressing the phosphorylation of ERK, JNK, and p38 that drives pathological cell growth.

Microbiome and Natural Compound Synergy

A recurring theme in this research is the use of "indirect" modulators—substances that don't just target a kinase directly but change the environment to favor signaling balance.

  • Probiotics: Wei Liang showed that Lactiplantibacillus plantarum reduces gut inflammation by downregulating the PI3K/AKT and NF-κB axes.
  • Natural Compounds: From garlic-derived SAMC (targeting JNK/p38) to Astragalus membranaceus (targeting ERK1/2), these compounds serve as multi-target tools that dampen the "noise" of overactive signaling pathways.

By focusing on these shared molecular bottlenecks—MAPK and NF-κB—researchers are finding that vastly different diseases can be treated with a unified strategy: restoring the cell's ability to turn its own switches off.

Papers in this version

History & citationVersion 1 · 2026-10-04

Merged into another direction · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_therapeutic_modulation_of_mapk_and_nf_ka_e29e6a98,
  title = {Therapeutic Modulation of MAPK and NF-kappaB Signaling Pathways},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/therapeutic-modulation-of-mapk-and-nf-kappab-signaling-pathways/rdr_e29e6a98d746474e941b13e4fc37a7cc},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}

This exact version (version 1, frozen text):

@misc{lacuna_therapeutic_modulation_of_mapk_and_nf_ka_e29e6a98_v1,
  title = {Therapeutic Modulation of MAPK and NF-kappaB Signaling Pathways},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/therapeutic-modulation-of-mapk-and-nf-kappab-signaling-pathways/rdr_e29e6a98d746474e941b13e4fc37a7cc/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-20},
}